Idorsia Ltd (SW:IDIA) — Market Cap & Net Worth
Market Cap & Net Worth: Idorsia Ltd (IDIA)
Idorsia Ltd (SW:IDIA) has a market capitalization of $759.27 Million (CHF600.56 Million) as of May 2, 2026. Listed on the SW stock exchange, this Switzerland-based company holds position #10420 globally and #126 in its home market, demonstrating a -2.59% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Idorsia Ltd's stock price CHF3.68 by its total outstanding shares 245718315 (245.72 Million). Analyse Idorsia Ltd (IDIA) cash conversion ratio to see how efficiently the company converts income to cash.
Idorsia Ltd Market Cap History: 2017 to 2026
Idorsia Ltd's market capitalization history from 2017 to 2026. Data shows change from $7.91 Billion to $1.14 Billion (-13.72% CAGR).
Idorsia Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Idorsia Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.27x
Idorsia Ltd's market cap is 2.27 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $7.91 Billion | $158.09 Million | -$14.27 Million | 50.01x | N/A |
| 2018 | $5.04 Billion | $60.62 Million | -$386.39 Million | 83.12x | N/A |
| 2019 | $9.30 Billion | $23.82 Million | -$494.65 Million | 390.49x | N/A |
| 2020 | $7.93 Billion | $71.76 Million | -$445.12 Million | 110.48x | N/A |
| 2021 | $5.79 Billion | $35.35 Million | -$634.60 Million | 163.81x | N/A |
| 2022 | $4.17 Billion | $97.10 Million | -$827.90 Million | 42.93x | N/A |
| 2023 | $656.72 Million | $152.39 Million | -$297.92 Million | 4.31x | N/A |
| 2024 | $255.36 Million | $112.51 Million | -$263.76 Million | 2.27x | N/A |
Competitor Companies of IDIA by Market Capitalization
Companies near Idorsia Ltd in the global market cap rankings as of May 2, 2026.
Key companies related to Idorsia Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Idorsia Ltd Historical Marketcap From 2017 to 2026
Between 2017 and today, Idorsia Ltd's market cap moved from $7.91 Billion to $ 1.14 Billion, with a yearly change of -13.72%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CHF1.14 Billion | -13.42% |
| 2025 | CHF1.32 Billion | +417.64% |
| 2024 | CHF255.36 Million | -61.12% |
| 2023 | CHF656.72 Million | -84.25% |
| 2022 | CHF4.17 Billion | -28.00% |
| 2021 | CHF5.79 Billion | -26.96% |
| 2020 | CHF7.93 Billion | -14.76% |
| 2019 | CHF9.30 Billion | +84.59% |
| 2018 | CHF5.04 Billion | -36.27% |
| 2017 | CHF7.91 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Idorsia Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $759.27 Million USD |
| MoneyControl | $759.27 Million USD |
| MarketWatch | $759.27 Million USD |
| marketcap.company | $759.27 Million USD |
| Reuters | $759.27 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Idorsia Ltd
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the… Read more